Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe

作者：Yuyang Sun, Kai Xu, Hongting Yao, Jingxuan Wei, Baolong Ding, Xiaodan Qian, Dan Su, Jinhong Gong, Jingjing Shang, Lingli Zhang, Xin Li · 发表于：International Journal of Clinical Pharmacy · 年份：2024 · DOI：10.1007/s11096-024-01824-9 · 被引用次数：8 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Hepatitis B Virus Studies、Cancer Immunotherapy and Biomarkers